401 related articles for article (PubMed ID: 31492561)
1. Development and validation of a CIMP-associated prognostic model for hepatocellular carcinoma.
Li G; Xu W; Zhang L; Liu T; Jin G; Song J; Wu J; Wang Y; Chen W; Zhang C; Chen X; Ding Z; Zhu P; Zhang B
EBioMedicine; 2019 Sep; 47():128-141. PubMed ID: 31492561
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of CpG island methylator phenotype among hepatocellular carcinoma patients: A systematic review and meta-analysis.
Wang Q; Wang G; Liu C; He X
Int J Surg; 2018 Jun; 54(Pt A):92-99. PubMed ID: 29698791
[TBL] [Abstract][Full Text] [Related]
3. CpG island methylator phenotype associated with tumor recurrence in tumor-node-metastasis stage I hepatocellular carcinoma.
Li B; Liu W; Wang L; Li M; Wang J; Huang L; Huang P; Yuan Y
Ann Surg Oncol; 2010 Jul; 17(7):1917-26. PubMed ID: 20112070
[TBL] [Abstract][Full Text] [Related]
4. Correlation of CpG island methylator phenotype with poor prognosis in hepatocellular carcinoma.
Cheng Y; Zhang C; Zhao J; Wang C; Xu Y; Han Z; Jiang G; Guo X; Li R; Bu X; Wu M; Wei L
Exp Mol Pathol; 2010 Feb; 88(1):112-7. PubMed ID: 19879258
[TBL] [Abstract][Full Text] [Related]
5. [Correlations of CpG island methylator phenotype and OPCML gene methylation to carcinogenesis of hepatocellular carcinoma].
Liu WJ; Wang L; Wang JP; Li JQ; Zhang CQ; Zheng L; Yuan YF
Ai Zheng; 2006 Jun; 25(6):696-700. PubMed ID: 16764763
[TBL] [Abstract][Full Text] [Related]
6. Integrative analysis of DNA methylation and gene expression reveals hepatocellular carcinoma-specific diagnostic biomarkers.
Cheng J; Wei D; Ji Y; Chen L; Yang L; Li G; Wu L; Hou T; Xie L; Ding G; Li H; Li Y
Genome Med; 2018 May; 10(1):42. PubMed ID: 29848370
[TBL] [Abstract][Full Text] [Related]
7. Integrative analysis of h-prune as a potential therapeutic target for hepatocellular carcinoma.
Liao H; Liao M; Xu L; Yan X; Ren B; Zhu Z; Yuan K; Zeng Y
EBioMedicine; 2019 Mar; 41():310-319. PubMed ID: 30665854
[TBL] [Abstract][Full Text] [Related]
8. CpG island methylator phenotype association with elevated serum alpha-fetoprotein level in hepatocellular carcinoma.
Zhang C; Li Z; Cheng Y; Jia F; Li R; Wu M; Li K; Wei L
Clin Cancer Res; 2007 Feb; 13(3):944-52. PubMed ID: 17289889
[TBL] [Abstract][Full Text] [Related]
9. Prognostic implications of aberrantly expressed methylation‑driven genes in hepatocellular carcinoma: A study based on The Cancer Genome Atlas.
Li J; Chen N; Gong X
Mol Med Rep; 2019 Dec; 20(6):5304-5314. PubMed ID: 31661127
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of CpG island methylator phenotype for tumor recurrence in hepatitis B virus-associated hepatocellular carcinoma following liver transplantation.
Wu LM; Zhang F; Zhou L; Yang Z; Xie HY; Zheng SS
BMC Cancer; 2010 Aug; 10():399. PubMed ID: 20678188
[TBL] [Abstract][Full Text] [Related]
11. Identification of Prognostic Genes in the Tumor Microenvironment of Hepatocellular Carcinoma.
Xiang S; Li J; Shen J; Zhao Y; Wu X; Li M; Yang X; Kaboli PJ; Du F; Zheng Y; Wen Q; Cho CH; Yi T; Xiao Z
Front Immunol; 2021; 12():653836. PubMed ID: 33897701
[No Abstract] [Full Text] [Related]
12. CpG island methylator phenotype association with upregulated telomerase activity in hepatocellular carcinoma.
Zhang C; Guo X; Jiang G; Zhang L; Yang Y; Shen F; Wu M; Wei L
Int J Cancer; 2008 Sep; 123(5):998-1004. PubMed ID: 18546260
[TBL] [Abstract][Full Text] [Related]
13. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
[TBL] [Abstract][Full Text] [Related]
14. CpG island methylator phenotype in plasma is associated with hepatocellular carcinoma prognosis.
Liu JB; Zhang YX; Zhou SH; Shi MX; Cai J; Liu Y; Chen KP; Qiang FL
World J Gastroenterol; 2011 Nov; 17(42):4718-24. PubMed ID: 22180715
[TBL] [Abstract][Full Text] [Related]
15. Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data.
Liu S; Tang Q; Huang J; Zhan M; Zhao W; Yang X; Li Y; Qiu L; Zhang F; Lu L; He X
Aging (Albany NY); 2021 Apr; 13(8):11257-11280. PubMed ID: 33820866
[TBL] [Abstract][Full Text] [Related]
16. Identification of prognostic biomarkers associated with the occurrence of portal vein tumor thrombus in hepatocellular carcinoma.
Lin T; Lin Z; Mai P; Zhang E; Peng L
Aging (Albany NY); 2021 Apr; 13(8):11786-11807. PubMed ID: 33878734
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma.
Long J; Wang A; Bai Y; Lin J; Yang X; Wang D; Yang X; Jiang Y; Zhao H
EBioMedicine; 2019 Apr; 42():363-374. PubMed ID: 30885723
[TBL] [Abstract][Full Text] [Related]
18. Integrated analysis of methylation-driven genes and pretreatment prognostic factors in patients with hepatocellular carcinoma.
He D; Liao S; Cai L; Huang W; Xie X; You M
BMC Cancer; 2021 May; 21(1):599. PubMed ID: 34034705
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive molecular and immunological characterization of hepatocellular carcinoma.
Shimada S; Mogushi K; Akiyama Y; Furuyama T; Watanabe S; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Kudo A; Arii S; Tanabe M; Wands JR; Tanaka S
EBioMedicine; 2019 Feb; 40():457-470. PubMed ID: 30598371
[TBL] [Abstract][Full Text] [Related]
20. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
